Homburger advised UBS on the completion (on May 13th) of its issuance of USD 1.75 bn fixed rate / fixed rate callable senior notes due to september 2030. The Notes are bail-inable (TLAC) bonds that are eligible to
Tags :Homburger
Homburger advised Biopas on its sale to Swixx Biopharma, a swiss-based global commercial platform focusing on guaranteeing access to innovative medicines worldwide. The founders of Biopas will become shareholders of Swixx Biopharma. The transaction is
Homburger advised Sonova as a borrower in a CHF 400 million term and revolving credit facility agreement governed by Swiss law. UBS Switzerland acted as the mandated lead arranger and agent for an international bank syndacate.
Homburger advised UBS Switzerland in its capacity as mandated lead arranger, bookrunner and agent regarding BKW ‘s new CHF 1 billion law governed revolving credit facility, which has a five-year term until 2029, with the option to
Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
Roche Finance Europe issued EUR 1.5 billion bonds guaranteed by Roche Holding, advised by Homburger. Advestra advised BNP Paribas and the banking syndicate on the placement. Banco Santander, BNP Paribas and UniCredit Bank acted as joint
Dufry One B.V. issued EUR 500m Bonds guaranteed by Avolta AG and its subsidiaries. BNP Paribas, BofA Securities Europe S.A., HSBC Continental Europe S.A., ING Bank N.V., Intesa Sanpaolo S.p.
The Swiss special purpose issuance vehicle Xtrackers Digital Markets ETC AG, simultaneously launched two series of crypto-linked Exchange Traded Products (ETPs). This falls under its program for the issuance of cryptocurrency-focused ETPs for professional and
On April 3, 2024, Meyer Burger Technology AG (SIX: MBTN) announced the successful completion of its rights offering, raising gross proceeds of CHF 206.75m. Shares not subscribed by shareholders were placed with institutional investors at the prevailing
Addex Therapeutics, a clinical-stage biopharmaceutical company, listed on the SIX Swiss Exchange and on the Nasdaq, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, announced the launch
